El exón CALR 9 indels son el segundo conductor más común en ET (~25-30%) y un WHO 2022 / ICC...

Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.

ID	`BMA-CALR-ET`
Tipo	Relevancia terapéutica
Situación	reviewed 2026-04-27 \| pending_clinical_signoff \| actionability review required
Enfermedades	`DIS-ET`
Fuentes	`SRC-CIVIC` `SRC-ESMO-MPN-2015` `SRC-NCCN-MPN-2025` `SRC-PT1-HARRISON-2005`

Hechos relativos a la posibilidad de adoptar medidas

Biomarcador	`BIO-CALR`
Variante	exón 9 indels — tipo-1/tipo-1-como (deleción de 52-bp) y tipo-2/tipo-2-como (5-bP inserción); ~25-30% de trombocitemia esencial
Enfermedad	`DIS-ET`
El nivel de ESCAT	IA
Combinaciones recomendadas	observation (very-low-risk CALR-mutated per SRC-ESMO-MPN-2015), low-dose aspirin (low-risk per SRC-NCCN-MPN-2025), hydroxyurea + aspirin (high-risk 1L per SRC-PT1-HARRISON-2005), interferon-alpha (preferred for younger high-risk per SRC-NCCN-MPN-2025)
Resumen de las pruebas	CALR exon 9 indels are the second most common driver in ET (~25-30%) and a WHO 2022 / ICC 2022 major diagnostic criterion in JAK2/MPL- negative cases (per SRC-NCCN-MPN-2025, SRC-ESMO-MPN-2015). CALR- mutated ET has lower thrombosis risk than JAK2-mutated ET, which feeds into IPSET-thrombosis stratification: very-low-risk CALR patients may be managed with observation alone; otherwise risk- stratified management identical to JAK2-positive ET (low-risk → aspirin; high-risk → hydroxyurea/IFN per SRC-PT1-HARRISON-2005).

Notas

ESCAT IA / OncoKB Level 1 — diagnostic criterion. CALR type-1 (52-bp deletion) is more common in PMF and confers better OS than type-2 per several retrospective series; type-2 is enriched in ET. CALR- specific therapeutics (anti-CALR monoclonal antibodies, e.g. INCA 033989) are in early-phase trials only; no in-repo source ingested yet. Source-gap: SRC-NCCN-MPN-2025 STUB.

Utilizado por

No se encuentran referencias inversas en el corpus YAML.